KPV dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 6 published studies are one click away.
Animal studies only Repair Also called Lys-Pro-Val
Common use ranges
From user guides and clinic write-ups. No drug label exists, and no study has tested these amounts in people. Good agreement on 200 to 500 mcg once daily. Sources are a telehealth page, a vendor and a community guide.
- Half-life
- Not measured in any published study
- How it is taken
- Subcutaneous injection (oral capsules are also common for gut use)
- How long people use it
- Usually 4 to 12 weeks, then reassess. One guide allows up to 16 weeks.
- Mixing used for the units
- 10 mg vial + 2 mL water. 1 unit on a U-100 insulin syringe = 50 mcg.
Pick your vial size and how much water you add. The units below change to match.
10 mg vial + 2 mL water: 1 unit = 50 mcg
| Tier | Each dose | Syringe units10 mg vial + 2 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Starting [1] | 200 mcg | 4 units 0.04 mL | once a day | 200 mcg once a day, then add about 100 mcg each week as tolerated | 6+ weeks |
| Typical [2] | 500 mcg | 10 units 0.10 mL | once a day | 250 to 500 mcg once a day. Some split it into 250 mcg every 12 hours | 20 days |
Good to know
- Most protocols cap the shot at 1 mg a day.
- Oral capsules run 500 mcg to 1 mg once or twice a day for gut focused use.
- No source described a separate higher amount for injury or flare-ups.
Sources for these amounts
- Starting: Pure Peptide, KPV 10mg Vial Dosage Protocol · Peptide Dosing Protocols, KPV (community range 200 to 500 mcg daily)
- Typical: Form Blends, KPV Dosage Protocols (250 to 500 mcg once daily, most cap at 1 mg) · Pure Peptide, KPV 10mg Vial Dosage Protocol (target 400 to 500 mcg by weeks 4 to 8) · Peptide Dosing Protocols, KPV
How long people use it: Form Blends · Pure Peptide
Take the KPV chart with you
Get a one-page printable chart for KPV, with the syringe units for each vial and water mix. We can also email you when a new KPV study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 6 published studies
No human dose data. No published human study of KPV states an amount given. Every figure on this page comes from animal studies.
Amounts given to animals in studies
Read this first. Every KPV study used a concentration (eye drops or drinking water), not a dose per kg, so it cannot be scaled to a person.
Every study used for this page
Proof grade: Animal studies only. No human dose data has been published. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 27458604Viennois et al., colitis-associated cancer 2016 | Mouse (AOM/DSS WT, and APC Min/+; n not in abstract) | 100 micromol/L KPV in drinking water (concentration) | Oral, drinking water | Continuous with DSS (2 cycles); APC Min/+ from week 5 to 18 | Weeks | Reduced colitis and tumor burden. Dose verified in full text only |
| PMID 16965771corneal wound, 2006 | Rabbit (n not in abstract) | 1, 5 or 10 mg/ml KPV, 30 microl, two drops | Topical eye drops | Four times a day | 4 days | Faster corneal epithelial healing, NO role tested |
| PMID 18092346Kannengiesser et al., IBD 2008 | Mouse: DSS colitis, CD45RB-hi transfer colitis, MC1R e/e | Not stated in the abstract | Not in abstract | Not in abstract | Not in abstract | Earlier recovery, less MPO. KPV saved all MC1R e/e mice from DSS death |
| PMID 18061177Dalmasso et al., Gastroenterology 2008 | Mouse, DSS and TNBS colitis | Not stated in the abstract | Drinking water | Not in abstract | Not in abstract | Oral KPV reduced inflammation. PMC full text blocked by captcha, not verified |
| PMID 28143741HA-KPV nanoparticles, 2017 | Mouse, colitis | Not stated in the abstract | Oral nanoparticle in hydrogel | Not in abstract | Not in abstract | Delivery system, not a free-KPV dose |
| PMID 34547895KPV/SH-PGA hydrogel, 2021 | Rat, TNBS colitis | Not stated in the abstract | Rectal hydrogel | Not in abstract | Not in abstract | Formulation study |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
Is there a human dose for KPV?
No published human study of KPV states an amount given. The figures on this page come from animal studies only.
Where do these KPV numbers come from?
From 6 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Animal studies only.
How long does KPV stay in the body?
No published study has measured the half-life of KPV, so nobody knows exactly how long one dose stays in the blood.
Is this a recommendation for how much KPV to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.